MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

A

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

19.17 -0.1

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

18.59

Max

19.58

Galvenie mērījumi

By Trading Economics

Ienākumi

67M

-681K

Pārdošana

-2.9M

17M

P/E

Sektora vidējais

48.528

88.032

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

327K

5.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+6.77% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 8. janv.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

24M

368M

Iepriekšējā atvēršanas cena

19.27

Iepriekšējā slēgšanas cena

19.17

Ziņu noskaņojums

By Acuity

10%

90%

2 / 373 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. janv. 21:14 UTC

Galvenie tirgus virzītāji

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

2026. g. 6. janv. 19:23 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4 Billion Hg Acquisition

2026. g. 6. janv. 17:41 UTC

Galvenie tirgus virzītāji

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

2026. g. 6. janv. 15:46 UTC

Iegādes, apvienošanās, pārņemšana

Advent International Leads InPost Takeover Offer, Sky News Says

2026. g. 6. janv. 15:37 UTC

Galvenie tirgus virzītāji

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

2026. g. 6. janv. 23:46 UTC

Tirgus saruna

Nikkei May Decline After Hitting Record High -- Market Talk

2026. g. 6. janv. 23:35 UTC

Tirgus saruna

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

2026. g. 6. janv. 23:19 UTC

Tirgus saruna

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

2026. g. 6. janv. 22:53 UTC

Tirgus saruna

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

2026. g. 6. janv. 22:03 UTC

Iegādes, apvienošanās, pārņemšana

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

2026. g. 6. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. janv. 21:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2026. g. 6. janv. 21:12 UTC

Tirgus saruna

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

2026. g. 6. janv. 20:59 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Deal Could Be Announced Imminently, Sources Say -- WSJ

2026. g. 6. janv. 20:40 UTC

Iegādes, apvienošanās, pārņemšana

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

2026. g. 6. janv. 20:01 UTC

Tirgus saruna

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

2026. g. 6. janv. 19:52 UTC

Tirgus saruna

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

2026. g. 6. janv. 19:46 UTC

Iegādes, apvienošanās, pārņemšana

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

2026. g. 6. janv. 19:08 UTC

Iegādes, apvienošanās, pārņemšana

OneStream to Go Private Through $6.4B Hg Acquisition

2026. g. 6. janv. 18:28 UTC

Iegādes, apvienošanās, pārņemšana

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

2026. g. 6. janv. 17:20 UTC

Tirgus saruna
Peļņas

Financial Services Roundup: Market Talk

2026. g. 6. janv. 17:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Health Care Roundup: Market Talk

2026. g. 6. janv. 15:57 UTC

Tirgus saruna

Crude Futures Ease Back From Early Gains -- Market Talk

2026. g. 6. janv. 15:34 UTC

Tirgus saruna
Peļņas

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

2026. g. 6. janv. 15:27 UTC

Tirgus saruna

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

6.77% augšup

Prognoze 12 mēnešiem

Vidējais 20.5 USD  6.77%

Augstākais 25 USD

Zemākais 16 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

2 / 373 Rangs Veselības aprūpe

Ziņu noskaņojums

Ļoti spēcīga liecība "buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat